The HIV Functional Cure Potential of UB-421 in ART Stabilized HIV-1 Patients

Exclusion Criteria

• •1. Subjects with active systemic infections, except for HIV-1, that the Investigator feels the infections may confound evaluation and treatment for HIV-1.
• •2. Current active hepatitis B carriers, ie, hepatitis B surface antigen positive.
• •3. Current active hepatitis C carriers, ie, hepatitis C virus (HCV) antibody positive.
• •4. History of anaphylaxis to other mAbs.
• •5. Any vaccination within 8 weeks prior to the first dose of assigned drug.
• •6. Use of immunomodulators, HIV vaccine, or systemic chemotherapy within 180 days prior to the first dose of assigned drug.
• •7. Females who are pregnant, lactating, or breastfeeding, or who plan to become pregnant during the study.